



**PHARMACY AND THERAPEUTICS COMMITTEE
ACA/Exchange MEETING MINUTES
May 13, 2025**

*Attendance: Microsoft Teams Meeting
Yumna Ahmed, Pharmacy Student Intern; Dr. Paul Aitken, Medical Director; Dr. Rick Buzard, Associate Chief Medical Officer; Connie Chan, Staff/Clinical Pharmacist; Dr. Edgar Chou, Jefferson Health; Jerry Crawford, Staff/Clinical Pharmacist; Dr. Neal Demp, Community Behavior Health; Danielle Dolores, Director of Pharmacy; Dr. George E. Downs, Dean Emeritus and Professor, St. Joseph's University; Leah Finken, Clinical Programs Pharmacist; Sharon Ford, Staff/Clinical Pharmacist; Hailey Fry, Centennial Pharmacy; Paul Goebel, Assistant Director Pharmacy, Jefferson Enterprise; Dr. Merleen Harris-Williams, Medical Director; Yelena Hedrick, Staff/Clinical Pharmacist; Samantha Jackson, Clinical Pharmacist; Ruth John, Pharmacy Resident; Lawrence Jones, Retired Executive Director, Pennsylvania Society of Health-System Pharmacists (PSHP); Kaylei Koerwitz, Manager Pharmacy Operations and Clinical Programs; Dr. Tania Kolev, Medical Director; Hannah McCaffrey, Manager Pharmacy Regulations & Implementation; Brandi Mahler, Supervisor Pharmacy Technicians; Lisa Murray, Staff/Clinical Pharmacist; Kateryna Olchowecky, Clinical Programs Pharmacist; Maryana Prokopets, Staff/Clinical Pharmacist; Sara Sadiq, Staff/Clinical Pharmacist; Julie Samuel, Clinical Programs Pharmacist; Heather Scheckner, Clinical Pharmacist, Jefferson Health; Mike Smikovecus, Staff/Clinical Pharmacist; Robert Spencer, Staff/Clinical Pharmacist; Shelley Staffa, Clinical Pharmacist; Justin Steffan, Pharmacy Resident; Jessica Tran, Staff/Clinical Pharmacist; Fallan Vaisberg, Formulary Pharmacist; Ramesh Vangala, Vice President of Pharmacy Operations; Jeanine Zubrzycki, Staff/Clinical Pharmacist*

Excused: Gary Bledsoe, Staff/Clinical Pharmacist; Dr. Kevin Caputo, Magellan Health; Dr. Demian Elder, Medical Director; Sanjiv Raj, Associate VP Customer Engagement; Dr. Chris Squillaro, Medical Director, Magellan Behavioral Health; Brian Swift, Enterprise Vice President/Chief Pharmacy Officer, Jefferson Health

Minutes taken by: Joana Iverson

I. Administrative Update

TOPIC	DISCUSSION	ACTIONS	RESPONSIBLE PARTY	RESOLVED/PENDING
<i>Minutes Review/Approval</i>	<i>D. Dolores presented the minutes from the March 2025 meeting to the Committee for review.</i>	<i>The Committee approved the minutes from our last meeting as presented.</i>	<i>D. Dolores</i>	<i>Resolved</i>

II. Prior Authorization Review/Updates

TOPIC	DISCUSSION	ACTIONS	RESPONSIBLE PARTY	RESOLVED/PENDING
<p>2026 Formulary Additions</p>	<p><i>The Committee reviewed the Formulary Additions. The Committee approved as presented.</i></p> <ul style="list-style-type: none"> • <i>Advate - T5, PA</i> • <i>Adynovate - T5, PA</i> • <i>Afstyla - T5, PA</i> • <i>Alphanate - T5, PA</i> • <i>AlphaNine SD - T5, PA</i> • <i>Alprolix - T5, PA</i> • <i>Altuviiiio - T5, PA</i> • <i>BeneFIX - T5, PA</i> • <i>Brimonidine tartrate 0.1% solution - T2</i> • <i>Eloctate - T5, PA</i> • <i>Feiba - T5, PA</i> • <i>Hemlibra - T5, PA</i> • <i>Hemofil M - T5, PA</i> • <i>Humate-P - T5, PA</i> • <i>Ixinity - T5, PA</i> • <i>Jivi - T5, PA</i> • <i>Koate - T5, PA</i> • <i>Koate-DVI - T5, PA</i> • <i>Kogenate FS - T5, PA</i> • <i>Kovaltry - T5, PA</i> • <i>Lantus - T3</i> • <i>Lantus SoloStar - T3</i> • <i>Mononine - T5, PA</i> • <i>Novoeight - T5, PA</i> • <i>NovoSeven RT - T5, PA</i> • <i>Nuwiq - T5, PA</i> • <i>Profilnine - T5, PA</i> • <i>Qulipta - T3, QL 30/30 days, PA</i> • <i>Rebinyn - T5, PA</i> • <i>Recombinate - T5, PA</i> • <i>Rixubis - T5, PA</i> • <i>Sevenfact - T5, PA</i> • <i>Tazarotene 0.05% cream - T2, PA</i> • <i>Velsipity - T5, PA</i> • <i>Wilate - T5, PA</i> • <i>Xyntha - T5, PA</i> • <i>Xyntha Solofuse - T5, PA</i> 	<p><i>The Committee approved as presented.</i></p>	<p><i>H. McCaffrey</i></p>	<p><i>Resolved</i></p>

TOPIC	DISCUSSION	ACTIONS	RESPONSIBLE PARTY	RESOLVED/ PENDING
2026 Formulary Removals	<p>The Committee reviewed the Formulary Removals.</p> <ul style="list-style-type: none"> • Alphagan P (generic covered) • APO-varenicline • Avonex Pen • Avonex Prefilled Syringe • Basaglar KwikPen • Fuzeon • Gomekli • Hetlioz LQ • Iclusig • Invega Hafyera • Invega Trinza • Ketoprofen • Ketoprofen ER • Levemir • Levemir FlexTouch • Lexiva suspension • Lucemyra (generic covered) • Methamphetamine 5 mg tablet • Myrbetriq (generic covered) • Natpara • Nitrolingual • Nucala • Plegridy • Ridaura (generic covered) • Simponi • Simponi Aria • Sprycel (generic covered) • Trientine 500 mg capsule • Verzenio • Viracept • Xyrem (generic covered) • Yonsa 	<p>The Committee approved as presented.</p>	<p>H. McCaffrey</p>	<p>Resolved</p>
2026 Tier Changes	<p>The Committee reviewed the Tier Changes. The Committee approved as presented.</p> <ul style="list-style-type: none"> • Cabenuva - Move to T4 • Clovique/trientine - Move to T2 • Descovy - Move to T0 • Emtricitabine-Tenofovir DF - Move to T0 • Mesna - Move to T2 	<p>The Committee approved as presented.</p>	<p>H. McCaffrey</p>	<p>Resolved</p>

TOPIC	DISCUSSION	ACTIONS	RESPONSIBLE PARTY	RESOLVED/PENDING
	<ul style="list-style-type: none"> • Paxlovid - Move to T2 • Repatha Pushtronex System - Move to T3 • Sublocade - Move to T3 • Symtuza - Move to T3 • Triumeq/Triumeq PD - Move to T4 			


III. Drug Formulary Review/Update

2025 Prior Authorization Review	<p>The Committee reviewed the Prior Authorization updates and approved as presented.</p> <ul style="list-style-type: none"> • Xdemvy • Strensiq 	The Committee reviewed the Prior Authorization updates and approved as presented.	J. Crawford F. Vaisberg	Resolved
2025 Formulary Additions	<p>The Committee reviewed the 2025 Formulary Additions and approved as presented.</p> <ul style="list-style-type: none"> • Adalimumab-adaz 10 mg/0.1mL soln prsy - T5, PA • Amnesteem 30 mg cap - T2, PA • Auranofin 3 mg cap - T4 • Feirza 1/20 1-20 mg-mcg tab - T0 • Ft naloxone hcl 4 mg/0.1mL liquid - T1 • Gomekli 1 mg cap - T5, PA • Gomekli 1 mg tab sol - T5, PA • Gomekli 2 mg cap - T5, PA • Kaletra 400-100 mg/5mL solution - T3, QL 480/30 • Multivitamin/fluoride 0.25 mg/mL solution - T2 • Ondansetron hcl +rfd 4 mg/2mL solution - T2 • Paxlovid 6 x 150 mg & 5 x 100mg tab thpk - T3, QL 30/30 • Pitavastatin calcium 1 mg tablet - T0, 30/30 days • Pitavastatin calcium 2 mg tablet - T0, 30/30 days • Pitavastatin calcium 4 mg tablet - T0, 30/30 days • Retaine allergy 0.2 % solution - T2 • Revuforj 110 mg tab - T5, PA • Revuforj 160 mg tab - T5, PA • Revuforj 25 mg tab - T5, PA • Tremfya crohns induction 200 mg/2mL soln a-inj - T5, PA • Tremfya pen 100 mg/ml soln a-inj - T5, PA • Xarah fe 1-20/1-30/1-35 mg-mcg tab - T0 • Xelria fe 0.4-35 mg-mcg chew tab - T0 • Xpovio (40 mg once weekly) 10 mg tab thpk - T5, PA 	The Committee reviewed the 2025 Formulary Additions and approved as presented.	F. Vaisberg	Resolved

IV. New Drug Review	<i>(Presented in New Drug Review for Medicaid.) The following new products were reviewed and will be kept as non-formulary: *Refer to May 2025 Medicare Minutes</i>	<i>The Committee approved the New Drug Review as presented and recommended.</i>	<i>R. John</i>	<i>Resolved</i>
----------------------------	---	---	----------------	-----------------

V. Adjournment

There being no further business to discuss, the meeting was adjourned. Next meeting is to be held August 2025.



5/22/2025

Danielle Dolores, Director of Pharmacy Services

Date